126 related articles for article (PubMed ID: 37922945)
21. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
[TBL] [Abstract][Full Text] [Related]
22. MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.
Zhai Y; Iura A; Yeasmin S; Wiese AB; Wu R; Feng Y; Fearon ER; Cho KR
Oncogene; 2011 Oct; 30(40):4152-62. PubMed ID: 21499300
[TBL] [Abstract][Full Text] [Related]
23. [Expression and significance of p-AKT, p-GSK3β and β-catenin in epithelial carcinoma of ovary].
Wei X; Lü QJ; Sun HX; Qi YF; Wang JO; Cao CC
Zhonghua Bing Li Xue Za Zhi; 2012 Feb; 41(2):86-90. PubMed ID: 22455883
[TBL] [Abstract][Full Text] [Related]
24. [Endometrioid adenocarcinoma with proliferated stromal cells, hyalinization and cord-like formations: A case report].
Ning BH; Zhang QX; Yang H; Dong Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):366-369. PubMed ID: 37042152
[TBL] [Abstract][Full Text] [Related]
25. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
Fadare O; Parkash V
Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
[TBL] [Abstract][Full Text] [Related]
26. CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
[TBL] [Abstract][Full Text] [Related]
27. Endometrioid adenocarcinoma of the ovary mimicking serous borderline tumor: report of a series of cases.
Mansor S; McCluggage WG
Int J Gynecol Pathol; 2014 Sep; 33(5):470-6. PubMed ID: 25083962
[TBL] [Abstract][Full Text] [Related]
28. Nuclear β-Catenin Expression in the Context of Abnormal p53 Expression Indicates a Nonserous Histotype in Endometrial Carcinoma.
Keyhanian K; Yang EJ; Howitt BE
Int J Gynecol Pathol; 2023 Sep; 42(5):435-442. PubMed ID: 36731035
[TBL] [Abstract][Full Text] [Related]
29. Carcinosarcoma of female urethra with melanocytic differentiation.
Liu J; Wu H
Int J Clin Exp Pathol; 2011 Jan; 4(2):206-9. PubMed ID: 21326817
[TBL] [Abstract][Full Text] [Related]
30. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Logani S; Oliva E; Arnell PM; Amin MB; Young RH
Mod Pathol; 2005 Jan; 18(1):19-25. PubMed ID: 15389251
[TBL] [Abstract][Full Text] [Related]
31. PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression.
Tanwar PS; Kaneko-Tarui T; Lee HJ; Zhang L; Teixeira JM
Carcinogenesis; 2013 Apr; 34(4):893-901. PubMed ID: 23276799
[TBL] [Abstract][Full Text] [Related]
32. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers.
Ramalingam P; Masand RP; Euscher ED; Malpica A
Int J Gynecol Pathol; 2016 Sep; 35(5):410-8. PubMed ID: 26598976
[TBL] [Abstract][Full Text] [Related]
33. Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2.
Houghton O; Connolly LE; McCluggage WG
Histopathology; 2008 Aug; 53(2):156-65. PubMed ID: 18752499
[TBL] [Abstract][Full Text] [Related]
34. Biological relevance of E-cadherin-catenin complex proteins in primary epithelial ovarian tumours.
Faleiro-Rodrigues C; Macedo-Pinto IM; Maia SS; Vieira RH; Lopes CS
Gynecol Obstet Invest; 2005; 60(2):75-83. PubMed ID: 15785075
[TBL] [Abstract][Full Text] [Related]
35. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma.
Karnezis AN; Aysal A; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2013 Jan; 37(1):24-37. PubMed ID: 23108017
[TBL] [Abstract][Full Text] [Related]
36. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
Xiong Y; Xiong YY; Zhou YF
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
[TBL] [Abstract][Full Text] [Related]
37. Low grade endometrial endometrioid adenocarcinoma: A review and update with emphasis on morphologic variants, mimics, immunohistochemical and molecular features.
Lucas E; Carrick KS
Semin Diagn Pathol; 2022 May; 39(3):159-175. PubMed ID: 35397943
[TBL] [Abstract][Full Text] [Related]
38. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms.
Tafe LJ; Garg K; Chew I; Tornos C; Soslow RA
Mod Pathol; 2010 Jun; 23(6):781-9. PubMed ID: 20305618
[TBL] [Abstract][Full Text] [Related]
39. Mesonephric-like Differentiation of Ovarian Endometrioid and High-grade Serous Carcinomas: Clinicopathological and Molecular Characteristics Distinct from Those of Mesonephric-like Adenocarcinoma.
Choi KH; Kim H; Bae GE; Lee SH; Woo HY; Kim HS
Anticancer Res; 2021 Sep; 41(9):4587-4601. PubMed ID: 34475087
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.
Voutilainen KA; Anttila MA; Sillanpää SM; Ropponen KM; Saarikoski SV; Juhola MT; Kosma VM
J Clin Pathol; 2006 May; 59(5):460-7. PubMed ID: 16461565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
